{
    "info": {
        "nct_id": "NCT04774393",
        "official_title": "Phase 1b/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib",
        "inclusion_criteria": "* Patients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML) (including biphenotypic or bilineage leukemia including a myeloid component or isolated extramedullary AML); OR\n* Patients (> 60 year old) with newly diagnosed AML not eligible for intensive chemotherapy are also eligible\n* To be considered not eligible for intensive chemotherapy, participants must be defined by the following: Age 75 years or older, or Age 18 to 74 years with at least one of the following comorbidities:\n* Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction ≤50%, or chronic stable angina).\n* Severe pulmonary disorder (eg, DLCO ≤65% or forced expiratory volume in 1 second [FEV1] ≤65%).\n* Creatinine clearance ≥30 mL/min to <45 mL/min.\n* Moderate hepatic impairment with total bilirubin >1.5 to ≤3.0 × upper limit of normal (ULN)\n* ECOG performance status of 2 or 3\n* Age >= 18 years\n* Subjects must have documented IDH1 or IDH2 gene mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Adequate renal function including creatinine < 2 unless related to the disease\n* Direct bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\n* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5 x ULN will be considered eligible)\n* In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy agent(s). Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principle investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\n* Male subjects who are sexually active with a women of childbearing potential (WOCBP) and who have not had vasectomies must be willing to use a barrier method of contraception and refrain from sperm donation from initial study drug until 90 days after last dose of study drug\n* Willing and able to provide informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\n* Patients with any concurrent uncontrolled clinically significant medical condition including life-threatening severe infection, or psychiatric illness, which could place the patient at unacceptable risk of study treatment\n* Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)\n* Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications\n* Corrected QT (QTc) interval using Fridericia's formula (QTcF) >= 450 msec. Bundle branch block and prolonged QTc interval are permitted after discussion with the PI\n* Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection\n* Subject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion)\n* Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception\n\n  * Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Creatinine clearance ≥30 mL/min to <45 mL/min.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ≥30 mL/min to <45 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "mL/min"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 45,
                                        "unit": "mL/min"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* To be considered not eligible for intensive chemotherapy, participants must be defined by the following: Age 75 years or older, or Age 18 to 74 years with at least one of the following comorbidities:",
            "criterions": [
                {
                    "exact_snippets": "Age 75 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Age 18 to 74 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 74,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one of the following comorbidities",
                    "criterion": "comorbidities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "comorbidity"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction ≤50%, or chronic stable angina).",
            "criterions": [
                {
                    "exact_snippets": "Severe cardiac disorder (eg, congestive heart failure requiring treatment",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ejection fraction ≤50%",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic stable angina",
                    "criterion": "chronic stable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function including creatinine < 2 unless related to the disease",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine < 2 unless related to the disease",
                    "criterion": "creatinine level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless related to the disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 2 or 3",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 2 or 3",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Direct bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement",
            "criterions": [
                {
                    "exact_snippets": "Direct bilirubin < 2 x upper limit of normal (ULN)",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless increase is due to Gilbert's disease",
                    "criterion": "direct bilirubin increase due to Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless increase is due to ... leukemic involvement",
                    "criterion": "direct bilirubin increase due to leukemic involvement",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients (> 60 year old) with newly diagnosed AML not eligible for intensive chemotherapy are also eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients (> 60 year old)",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "newly diagnosed AML",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "not eligible for intensive chemotherapy",
                    "criterion": "eligibility for intensive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy agent(s). Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principle investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted",
            "criterions": [
                {
                    "exact_snippets": "the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy agent(s)",
                    "criterion": "interval from prior treatment to initiation of study therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy",
                    "criterion": "use of oral hydroxyurea and/or cytarabine before study therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "g/m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted",
                    "criterion": "concurrent therapy for CNS prophylaxis or controlled CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML) (including biphenotypic or bilineage leukemia including a myeloid component or isolated extramedullary AML); OR",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of relapsed or refractory acute myeloid leukemia (AML)",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "biphenotypic or bilineage leukemia including a myeloid component",
                    "criterion": "biphenotypic or bilineage leukemia with myeloid component",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "isolated extramedullary AML",
                    "criterion": "isolated extramedullary AML",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate hepatic impairment with total bilirubin >1.5 to ≤3.0 × upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Moderate hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin >1.5 to ≤3.0 × upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "× ULN"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "× ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe pulmonary disorder (eg, DLCO ≤65% or forced expiratory volume in 1 second [FEV1] ≤65%).",
            "criterions": [
                {
                    "exact_snippets": "Severe pulmonary disorder",
                    "criterion": "pulmonary disorder",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "DLCO ≤65%",
                    "criterion": "DLCO",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "forced expiratory volume in 1 second [FEV1] ≤65%",
                    "criterion": "forced expiratory volume in 1 second (FEV1)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male subjects who are sexually active with a women of childbearing potential (WOCBP) and who have not had vasectomies must be willing to use a barrier method of contraception and refrain from sperm donation from initial study drug until 90 days after last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Male subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active with a women of childbearing potential (WOCBP)",
                    "criterion": "sexual activity with women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who have not had vasectomies",
                    "criterion": "vasectomy status",
                    "requirements": [
                        {
                            "requirement_type": "history of vasectomy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must be willing to use a barrier method of contraception",
                    "criterion": "use of barrier contraception",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refrain from sperm donation from initial study drug until 90 days after last dose of study drug",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from sperm donation",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "donations"
                            }
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "from initial study drug until 90 days after last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5 x ULN will be considered eligible)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... < 3 x ULN unless considered due to leukemic involvement",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless considered due to leukemic involvement, in which case direct bilirubin ... < 5 x ULN will be considered eligible",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless considered due to leukemic involvement, in which case ... AST and/or ALT < 5 x ULN will be considered eligible",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless considered due to leukemic involvement, in which case ... AST and/or ALT < 5 x ULN will be considered eligible",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects must have documented IDH1 or IDH2 gene mutation",
            "criterions": [
                {
                    "exact_snippets": "documented IDH1 or IDH2 gene mutation",
                    "criterion": "IDH1 gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented IDH1 or IDH2 gene mutation",
                    "criterion": "IDH2 gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to provide informed consent",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to provide informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis B (HBV) or hepatitis C (HCV) infection",
                    "criterion": "hepatitis B or hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "known human immunodeficiency virus (HIV) infection",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)",
            "criterions": [
                {
                    "exact_snippets": "Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "oral hormonal birth control",
                                "injectable hormonal birth control",
                                "intrauterine device (IUD)",
                                "double barrier methods (e.g., condom in combination with spermicide)"
                            ]
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)",
            "criterions": [
                {
                    "exact_snippets": "t(15;17) karyotypic abnormality",
                    "criterion": "t(15;17) karyotypic abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)",
                    "criterion": "acute promyelocytic leukemia (FAB class M3-AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)",
            "criterions": [
                {
                    "exact_snippets": "Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant",
                    "criterion": "active graft-versus-host-disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI",
                    "criterion": "chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "chronic suppressive immunosuppression",
                                "phototherapy for chronic skin GVHD"
                            ]
                        },
                        {
                            "requirement_type": "PI approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion)",
            "criterions": [
                {
                    "exact_snippets": "Subject has a white blood cell count > 25 x 10^9/L",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any concurrent uncontrolled clinically significant medical condition including life-threatening severe infection, or psychiatric illness, which could place the patient at unacceptable risk of study treatment",
            "criterions": [
                {
                    "exact_snippets": "any concurrent uncontrolled clinically significant medical condition",
                    "criterion": "clinically significant medical condition",
                    "requirements": [
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening severe infection",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "life-threatening"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential (WOCBP) with positive urine pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "urine pregnancy test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential who are not willing to maintain adequate contraception",
                    "criterion": "contraception willingness",
                    "requirements": [
                        {
                            "requirement_type": "willingness to maintain adequate contraception",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT (QTc) interval using Fridericia's formula (QTcF) >= 450 msec. Bundle branch block and prolonged QTc interval are permitted after discussion with the PI",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT (QTc) interval using Fridericia's formula (QTcF) >= 450 msec",
                    "criterion": "QTc interval (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Bundle branch block ... are permitted after discussion with the PI",
                    "criterion": "bundle branch block",
                    "requirements": [
                        {
                            "requirement_type": "permitted after discussion with the PI",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prolonged QTc interval are permitted after discussion with the PI",
                    "criterion": "prolonged QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "permitted after discussion with the PI",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications",
            "criterions": [
                {
                    "exact_snippets": "any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications",
                    "criterion": "gastrointestinal condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "interference with absorption of oral study medications",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications",
                    "criterion": "metabolic condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "interference with absorption of oral study medications",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}